M. Tsai

D. Basi, K. Swenson, B. Michalowicz, 2016, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

M. Erlander, S. Silberman, G. Schiller, 2020, Clinical Cancer Research.

Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)

J. Sloan, C. Loprinzi, T. Dockter, 2018, Supportive Care in Cancer.

Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study

V. Karantza, D. Patt, R. O'Regan, 2021, Clinical Cancer Research.

Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study.

Anand A. Dalal, G. Hortobagyi, B. Ramaswamy, 2019, Clinical breast cancer.

Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

A. Bergamaschi, F. Baehner, C. Escriu, 2020, npj Precision Oncology.

Utility of Oncotype DX Risk Assessment in Patients With Invasive Lobular Carcinoma.

K. Swenson, B. Susnik, Joel E Money, 2016, Clinical breast cancer.

Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw.

J. Hodges, K. Swenson, B. Michalowicz, 2014, Journal of periodontology.

Why Is Cancer Genetic Counseling Underutilized by Women Identified as at Risk for Hereditary Breast Cancer? Patient Perceptions of Barriers Following a Referral Letter

P. Mink, S. Baldinger, K. Swenson, 2017, Journal of Genetic Counseling.

A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1).

V. Karantza, D. Patt, R. O'Regan, 2020 .

245PDDuration of response and tumor shrinkage with first-line ribociclib + letrozole in postmenopausal women with HR+, HER2– ABC

P. Ward, F. Esteva, M. Campone, 2017 .

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

I. Lossos, A. Zelenetz, F. Awan, 2022, Blood.

Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer

Marilyn M. Li, L. Pusztai, R. Nanda, 2018 .

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

William Audeh, Pat Whitworth, Hatem Soliman, 2018, JAMA oncology.

Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.

M. Nissen, S. Henly, K. Swenson, 2013, Oncology nursing forum.

Abstract GS3-06: Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

L. Carey, A. Bardia, H. Rugo, 2021 .

Abstract PD1-06: Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer

S. Papish, S. Kuemmel, T. Pluard, 2020 .

Predictive value of breast magnetic resonance imaging in detecting mammographically occult contralateral breast cancer: Can we target women more likely to have contralateral breast cancer?

T. DeFor, K. Swenson, B. Susnik, 2018, Journal of surgical oncology.

Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).

M. Socinski, V. Velcheti, D. Fabrizio, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer Rehabilitation: Outcome Evaluation of a Strengthening and Conditioning Program

M. Nissen, K. Swenson, M. Tsai, 2014, Cancer nursing.

Effectiveness of treatment summaries in increasing breast and colorectal cancer survivors’ knowledge about their diagnosis and treatment

M. Nissen, A. Blaes, K. Swenson, 2013, Journal of Cancer Survivorship.

First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial

P. Ward, F. Esteva, M. Campone, 2018, Breast Cancer Research and Treatment.

Serum Markers of Bone Turnover and Angiogenesis in Bisphosphonate-related Osteonecrosis of the Jaw Patients Following Discontinuation of Long-term Intravenous Bisphosphonate Therapy

D. Basi, K. Swenson, B. Michalowicz, 2016 .

Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw.

T. Griffin, D. Basi, E. D. de Jong, 2015, Oral diseases.

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

Shaughnessy, O. J., L. Carey, 2022 .

A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease

J. Laubach, P. Richardson, I. Ghobrial, 2018, Blood.

HER2 Testing: Insights From Pathologists’ Perspective on Technically Challenging HER2 FISH Cases

K. Allison, M. Rendi, H. Yaziji, 2021, Applied immunohistochemistry & molecular morphology : AIMM.